MicroRNA-210 is upregulated by hypoxia-inducible factor-1a in the stromal cells of giant cell tumors of bone

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 6185-6192

  Guo, Shibing ^a   Bai, Rui ^a   Liu, Wanlin ^a   Zhao, Aiqing ^b   Zhao, Zhenqun ^a   Wang, Yuxin ^a   Wang, Yong ^a   Zhao, Wei ^a,b   Wang, Wenxuan ^a  

^a The Affiliated Hospital of Mongolia Medical College   (China)

^b First Affiliated Hospital of Inner Mongolia Medical University   (China)

Author keywords

Giant cell tumors of bone; Hypoxia inducible factor 1 ; microRNA 210; Stromal cells

Indexed keywords

DICER; DROSHA ENZYME; ENZYME; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 210; UNCLASSIFIED DRUG; HIF1A PROTEIN, HUMAN; MICRORNA; MIRN210 MICRORNA, HUMAN;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; MALE; OSTEOCHONDROMA; OSTEOCLASTOMA; PROTEIN EXPRESSION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; U2OS CELL LINE; UPREGULATION; WESTERN BLOTTING; YOUNG ADULT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GIANT CELL TUMOR OF BONE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICRORNAS; OSTEOSARCOMA; STROMAL CELLS; UP-REGULATION;

EID: 84940568123     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4170     Document Type: Article

References (60)

1. Campanacci M, Baldini N, Boriani S and Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am 69: 106-114, 1987.
2. Anract P, De Pinieux G, Cottias P, Pouillart P, Forest M and Tomeno B: Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop 22: 19-26, 1998.
3. Gamberi G, Serra M, Ragazzini P, et al: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep 10: 351-356, 2003.
4. Miszczyk L, Wydmanski J and Spindel J: Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys 49: 1239-1242, 2001.
5. Olivera P, Perez E, Ortega A, et al: Estrogen receptor expression in giant cell tumors of the bone. Hum Pathol 33: 165-169, 2002.
6. Melillo G: Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4: 601-605, 2006.
7. Lin SC, Liao WL, Lee JC and Tsai SJ: Hypoxia-regulated gene network in drug resistance and cancer progression. Exp Biol Med (Maywood) 239: 779-792, 2014.
8. Cummins EP and Taylor CT: Hypoxia-responsive transcription factors. Pfugers Arch 450: 363-371, 2005.
9. Licausi F, Weits DA, Pant BD, Scheible WR, Geigenberger P and van Dongen JT: Hypoxia responsive gene expression is mediated by various subsets of transcription factors and miRNAs that are determined by the actual oxygen availability. New Phytol 190: 442-456, 2011.
10. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
11. Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
12. 2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
13. Pouysségur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443, 2006.
14. Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
15. Blancher C, Moore JW, Talks KL, Houlbrook S and Harris AL: Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60: 7106-7113, 2000.
16. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
17. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
18. Pralhad T, Madhusudan S and Rajendrakumar K: Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 55: 1045-1053, 2003.
19. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
20. Taylor RM, Kashima TG, Knowles HJ and Athanasou NA: VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology. Lab Invest 92: 1398-1406, 2012.
21. Knowles HJ and Athanasou NA: Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol 215: 56-66, 2008.
22. Wülling M, Delling G and Kaiser E: The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum Pathol 34: 983-993, 2003.
23. Morgan T, Atkins GJ, Trivett MK, et al: Molecular profling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 167: 117-128, 2005.
24. Skubitz KM, Cheng EY, Clohisy DR, Thompson RC and Skubitz AP: Gene expression in giant-cell tumors. J Lab Clin Med 144: 193-200, 2004.
25. Atkins GJ, Haynes DR, Graves SE, et al: Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15: 640-649, 2000.
26. Cowan RW, Singh G and Ghert M: PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone. J Orthop Res 30: 877-884, 2012.
27. Xu M, Song ZG, Xu CX, et al: IL-17A stimulates the progression of giant cell tumors of bone. Clin Cancer Res 19: 4697-4705, 2013.
28. Rao VH, Singh RK, Delimont DC, et al: Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Int J Oncol 14: 291-300, 1999.
29. Kumta SM, Huang L, Cheng YY, Chow LT, Lee KM and Zheng MH: Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci 73: 1427-1436, 2003.
30. Kudo N, Ogose A, Ariizumi T, et al: Expression of bone morpho-genetic proteins in giant cell tumor of bone. Anticancer Res 29: 2219-2225, 2009.
31. Ambros V: MicroRNA pathways in fies and worms: growth, death, fat, stress and timing. Cell 113: 673-676, 2003.
32. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
33. Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113: 25-36, 2003.
34. Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
35. Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res 65: 3509-3512, 2005.
36. Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis 33: 1126-1133, 2012.
37. Zhao L, Chen X and Cao Y: New role of microRNA: carcino-genesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai) 43: 831-839, 2011.
38. Fan L, Wu Q, Xing X, Wei Y and Shao Z: MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai) 44: 407-414, 2012.
39. Duan Z, Choy E, Harmon D, et al: MicroRNA-199a-3p is down-regulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 10: 1337-1345.
40. Pan Z, Sun X, Shan H, et al: MicroRNA-101 inhibited postinfarct cardiac fbrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126: 840-850, 2012.
41. Yuan J, Chen L, Chen X, Sun W and Zhou X: Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res 40: 2090-2097, 2012.
42. van der Deen M, Taipaleenmaki H, Zhang Y, et al: MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem 288: 21307-21319, 2013.
43. Mao JH, Zhou R P, Peng AF, et al: microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN. Oncol Lett 4: 1125-1129, 2012.
44. Fasanaro P, Greco S, Lorenzi M, et al: An integrated approach for experimental target Identification of hypoxia-induced miR-210. J Biol Chem 284: 35134-35143, 2009.
45. Mizuno Y, Tokuzawa Y, Ninomiya Y, et al: miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. Febs Lett 583: 2263-2268, 2009.
46. Ramakrishnan A, Torok-Storb B and Pillai MM: Primary marrow-derived stromal cells: isolation and manipulation. Methods Mol Biol 1035: 75-101, 2013.
47. Wang XH, Zhao FJ, Han BM, et al: Primary stromal cells isolated from human various histological/pathological prostate have different phenotypes and tumor promotion role. Chin Med J (Engl) 124: 1700-1707, 2011.
48. Zhao JH, Luo Y, Jiang YG, He DL and Wu CT: Knockdown of β-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1α. Cancer Invest 29: 377-382, 2011.
49. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
50. Mutharasan RK, Nagpal V, Ichikawa Y and Ardehali H: microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt-and p53-dependent pathways and exerts cyto-protective effects. Am J Physiol Heart Circ Physiol 301: H1519-H1530, 2011.
51. Biswas S, Roy S, Banerjee J, et al: Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA 107: 6976-6981, 2010.
52. Riggi N, Suvà ML, De Vito C, et al: EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 24: 916-932, 2010.
53. Ban J, Jug G, Mestdagh P, et al: Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 30: 2173-2180, 2011.
54. Zuntini M, Salvatore M, Pedrini E, et al: MicroRNA profling of multiple osteochondromas: Identification of disease-specifc and normal cartilage signatures. Clin Genet 78: 507-516, 2010.
55. Mosakhani N, Pazzaglia L, Benassi MS, et al: MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. Histol Histopathol 28: 671-678, 2013.
56. Vogel S, Wottawa M, Farhat K, et al: Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent coflin phosphorylation. J Biol Chem 285: 33756-33763, 2010.
57. Fujita N, Markova D, Anderson DG, et al: Expression of prolyl hydroxylases (PHDs) is selectively controlled by HIF-1 and HIF-2 proteins in nucleus pulposus cells of the intervertebral disc: distinct roles of PHD2 and PHD3 proteins in controlling HIF-1alpha activity in hypoxia. J Biol Chem 287: 16975-16986, 2012.
58. Demidenko ZN and Blagosklonny MV: The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1alpha. Cell Cycle 10: 1557-1562, 2011.
59. Kelly TJ, Souza AL, Clish CB and Puigserver P: A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol 31: 2696-2706, 2011.
60. Krock BL, Skuli N and Simon MC: Hypoxia-induced angio-genesis: good and evil. Genes Cancer 2: 1117-1133, 2011.